Cytosorbents Corporation

CTSO Micro Cap

Healthcare · Medical Devices

Updated: Apr 5, 2026, 17:43 UTC

$0.58

+6.52% today

52W: $0.50 – $1.39

52W Low: $0.50 Position: 9.4% 52W High: $1.39

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

0.99x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$36.6M

Market Capitalization

Revenue Growth

41.6%

YoY Revenue Growth

Profit Margin

-22.12%

Net profit margin

ROE

-96.39%

Return on Equity

Beta

1.48

Market sensitivity

Short Interest

3.49%

% of float sold short

Avg. Volume

89,036

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

3 analysts

Avg. Price Target

$5.25

+800.51% upside

Target Range

$0.75 – $10.00

About the Company

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, to

Sector: Healthcare Industry: Medical Devices Country: United States Exchange: NCM